FXR 314
Alternative Names: FXR-314; MET-642Latest Information Update: 09 Jan 2025
Price :
$50 *
At a glance
- Originator Metacrine
- Developer Metacrine; Organovo Holdings
- Class Amides; Anti-inflammatories; Benzene derivatives; Cyclohexanes; Cyclopropanes; Hepatoprotectants; Pyrazoles; Small molecules
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Liver disorders
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Phase I Hepatic fibrosis; Inflammatory bowel diseases
- Preclinical Gastroenteritis
Most Recent Events
- 06 Jan 2025 Pharmacodynamics data from a preclinical trial in Inflammatory bowel disease released by Organovo Holdings
- 09 May 2024 Organovo Holdings plans a phase II trial in Inflammatory bowel disease
- 15 Apr 2024 Efficacy and adverse event data from a phase-II trial in Non-alcoholic steatohepatitis released by Organovo Holdings